Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VM-GD
- Development stage
- Unknown
- Lead developer
- ViGenCell
- Modality
- Cell Therapies
- Administration
- Intravenous (inferred From Standard Practice For Cell Therapies; Not Explicitly Stated In Sources)
01
Overview
VM-GD is a cell therapy product developed by ViGenCell. It is described as a cord blood-derived myeloid suppressor cell therapy, designed for immune modulation through the replacement or supplementation of specific immune cells. The primary mechanism involves "cell replacements," indicating that the therapeutic effect is achieved by introducing functional cells to restore or modulate immune system function. Its main indication under clinical investigation is graft versus host disease (GvHD), an immune-mediated complication often seen after allogeneic stem cell transplantation.
- Other names
- Cord blood-derived myeloid suppressor cell therapy
Beyond the preview
Go deeper on VM-GD.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VM-GD.